NCT05186285View on ClinicalTrials.gov

Single Ascending Dose Study of CM338 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

December 11, 2021

Primary Completion Date

July 27, 2022

Study Completion Date

July 27, 2022

Conditions
Healthy
Interventions
DRUG

CM338

CM338 : a humanized monoclonal antibody.

DRUG

Placebo

Placebo.

Trial Locations (1)

Unknown

PKUCare Luzhong Hospital, Zibo

Sponsors
All Listed Sponsors
lead

Keymed Biosciences Co.Ltd

INDUSTRY

NCT05186285 - Single Ascending Dose Study of CM338 in Healthy Volunteers | Biotech Hunter | Biotech Hunter